GlassScriptPhysician profile
Caroline Claar
NPI 1942673322
$2,785.04
in general payments reported to CMS, 2019-2025
28 companies · $2,785 in 2025
The $2,785 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $2,785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $603.54 | 2025 | |
| Lundbeck LLC | $287.70 | 2025 | Vyepti |
| Eisai INC. | $262.24 | 2025 | |
| Ucb, INC. | $234.84 | 2025 | Briviact, Zilbrysq, Rystiggo |
| Novartis Pharmaceuticals Corporation | $226.24 | 2025 | |
| Axsome Therapeutics, INC. | $162.57 | 2025 | Symbravo |
| Otsuka America Pharmaceutical, INC. | $124.67 | 2025 | Rexulti |
| Biogen, INC. | $121.03 | 2025 | Vumerity, Tysabri, Leqembi |
| Teva Pharmaceuticals USA, INC. | $112.97 | 2025 | Ajovy, Austedo Xr |
| Neurocrine Biosciences, INC. | $92.68 | 2025 | |
| Sk Life Science, INC. | $59.26 | 2025 | |
| Lilly USA, LLC | $57.32 | 2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $54.30 | 2025 | Wainua |
| Merz Pharmaceuticals, LLC | $41.19 | 2025 | Inbrija, Xeomin |
| Neurelis, INC. | $39.57 | 2025 | Valtoco |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $37.78 | 2025 | Crexont |
| Scilex Pharmaceuticals INC. | $36.93 | 2025 | |
| Argenx US, INC. | $31.20 | 2025 | Vyvgart Hytrulo |
| Ge Healthcare | $27.63 | 2025 | |
| Jazz Pharmaceuticals INC. | $26.38 | 2025 | |
| Genentech USA, INC. | $22.98 | 2025 | Ocrevus Zunovo |
| Supernus Pharmaceuticals, INC. | $22.09 | 2025 | Qelbree |
| Janssen Biotech, INC. | $21.51 | 2025 | |
| Mdd US Operations, LLC | $18.89 | 2025 | Qelbree |
| Acadia Pharmaceuticals INC | $16.05 | 2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $15.88 | 2025 | Ultomiris |
| Emd Serono, INC. | $14.11 | 2025 | |
| Cycle Pharmaceuticals INC | $13.49 | 2025 | Tascenso Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Claar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.